Active Clinical Trials

Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural Mesothelioma

By April 24, 2017 No Comments

Condition

Mesothelioma, Malignant

Estimated Enrollment: 22

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment

Study ID Numbers: ONC-2014-002

Study First Received: November 19, 2014

Last Updated: February 9, 2017

Estimated Primary Completion Date: December 2015

 

Primary Outcome Measures:

anti-tumor activity of Imatinib mesylate in combination with Gemcitabine|anti-tumor activity of Imatinib mesylate in combination with Gemcitabine in terms of Response Evaluation Criteria In Solid Tumors (RECIST) criteria|anti-tumor activity of Imatinib mesylate in combination with Gemcitabine in terms of overall survival (OS).|safety profile of the combination according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 3|molecular profile of patients

Sponsors and Collaborators:

Istituto Clinico Humanitas

Website Link: https://ClinicalTrials.gov/show/NCT02303899

Leave a Reply

Call Now ButtonCall Now